siponimod
Selected indexed studies
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. (Lancet, 2018) [PMID:29576505]
- Siponimod. (, 2012) [PMID:32011841]
- Siponimod for multiple sclerosis. (Cochrane Database Syst Rev, 2021) [PMID:34783010]
_Worker-drafted node — pending editorial review._
Connections
siponimod is a side effect of
Sources
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. (2018) pubmed
- Siponimod. (2012) pubmed
- Siponimod for multiple sclerosis. (2021) pubmed
- Siponimod. (2006) pubmed
- Siponimod to treat secondary progressive multiple sclerosis. (2020) pubmed
- Siponimod in the treatment of multiple sclerosis. (2019) pubmed
- Pharmacogenetics of siponimod: A systematic review. (2022) pubmed
- Siponimod (Mayzent®). (1994) pubmed
- Siponimod (Mayzent®). (1994) pubmed
- Siponimod Therapy and CYP2C9 Genotype. (2012) pubmed